evipedia.ai
← Back

Glycine for Health & Longevity

Evidence Review created on 09/10/2026 using AI4L / Opus 5

Also known as: Aminoacetic Acid, Glycocoll, Gly, E640

Motivation

Glycine (aminoacetic acid) is the smallest of the twenty amino acids the body uses to build proteins. Some is made internally from other nutrients and the rest comes from food, mainly from skin, bone and connective tissue — the parts of an animal that modern eating habits usually discard. Interest in it comes from the number of jobs it holds: it supplies about a third of collagen, feeds the making of the body’s main internal antioxidant, and acts as a calming signal in the brain and spinal cord.

The compound has been sold as an inexpensive, faintly sweet powder for decades. Attention widened when feeding extra glycine lengthened life in laboratory animals, and when small human studies reported changes in sleep, blood pressure and markers of oxidative damage. Older adults and people carrying excess weight tend to have lower blood levels, which raised the question of whether topping them up changes anything that matters.

This review sets out what the human and animal record actually shows: where glycine is used, what it appears to change, what it may cost in return, how it is dosed, and how solid or thin the underlying data are.

Benefits - Risks - Protocol - Conclusion

High-level overviews of glycine from expert podcasts, blogs and longevity commentary that discuss the amino acid itself rather than pooling trial results.

Content from one priority platform is not listed. Huberman Lab’s only glycine coverage on hubermanlab.com is a brief segment inside the broad Sleep Toolkit episode — ground the Attia episode covers in more depth — alongside AI-generated “Ask Huberman Lab” answer pages, which are excluded as AI-generated reference material.

Grokipedia

Glycine

A long-form encyclopedic entry covering glycine’s chemistry, biosynthesis, neurotransmitter roles and industrial uses, useful as an orientation layer before reading the clinical literature.

Examine

Glycine

Summarises 196 participants across four trials and two meta-analyses, grades the evidence for schizophrenia symptoms and sleep, and gives the studied dose range of 3–60 g daily.

ConsumerLab

Glycine Supplement Review & Top Pick

Compares glycine products on quality, value and taste, and reviews the claims for sleep, mood, overactive bladder and tinnitus (ringing in the ears) alongside side effects and drug interactions.

Systematic Reviews

Pooled evidence syntheses on glycine in humans, covering both supplemental intake and circulating glycine as a marker of later disease.

No meta-analysis addresses the long-term harms of glycine supplementation in healthy adults; the risk side of the ledger is represented here only by the adverse-event and clozapine findings embedded in the two schizophrenia syntheses.

Mechanism of Action

Glycine’s side chain is a single hydrogen atom, the smallest possible, and it works through four routes.

It is the rate-limiting substrate for glutathione, the cell’s principal internal antioxidant, which is why it is usually paired with a cysteine source such as N-acetylcysteine (a cysteine precursor). It is one of two obligatory co-agonists at the NMDA (N-methyl-D-aspartate, a glutamate receptor central to learning and signalling) receptor, which cannot open until glycine or D-serine occupies its site. It is also an inhibitory transmitter at glycine receptors in the brainstem and spinal cord, and it widens skin blood vessels, dropping core temperature — the same shift that normally precedes sleep. Finally, conjugation in the liver clears organic acids and foreign compounds, excreted as acylglycines (glycine-tagged waste).

Pharmacologically, oral glycine is absorbed by sodium-dependent transporters, peaks in plasma within roughly 45 minutes, and clears with a half-life near one hour; brain entry is limited and needs gram-scale doses. It has no receptor selectivity in the usual sense and distributes to all tissues. Breakdown runs through the mitochondrial glycine cleavage system (GLDC, AMT and GCSH, the enzymes that dismantle glycine) and serine hydroxymethyltransferase (SHMT, which feeds glycine and serine into one-carbon metabolism, the body’s methyl-group supply line), not the cytochrome P450 family that handles most drugs.

Interpretations differ: one view treats glycine as conditionally essential, with internal synthesis falling short of demand. A competing view holds that in animals glycine mainly dilutes methionine, whose restriction independently extends lifespan.

Historical Context & Evolution

Glycine was isolated in 1820 by Henri Braconnot from boiled gelatin and named for its sweet taste. For most of the next century it was a chemical curiosity and a food ingredient; it still carries the additive number E640. Its first sustained clinical role was industrial rather than nutritional: from the mid-twentieth century a 1.5% glycine solution became the standard non-conducting fluid for flushing the bladder during prostate surgery, and the toxicity seen when large volumes were absorbed became the best-documented human glycine hazard.

Therapeutic interest arrived in waves. In the 1930s and 1940s glycine was tried in myasthenia gravis and muscular dystrophy (muscle-weakening disorders); those trials were uncontrolled and the approach faded without a decisive refutation, so the question was set aside rather than settled. In the 1990s the N-methyl-D-aspartate hypofunction model of schizophrenia produced controlled trials of glycine at 30–60 g daily, some positive and one large multicentre trial null — a split that remains unresolved rather than closed. Japanese work in the 2000s reported sleep benefits at 3 g, summarised in a review written by the manufacturer’s own researchers. Two later findings pushed glycine into the longevity conversation: correcting glutathione deficiency in older adults with glycine and cysteine, reported by the Baylor College of Medicine group that holds patent interests in the combination, and an 8% glycine diet extending lifespan in genetically diverse mice. Neither has yet been matched by a long human trial, so the current reading is provisional in both directions.

Expected Benefits

High 🟩 🟩 🟩

Improved Sleep Quality and Reduced Next-Day Fatigue

Glycine taken shortly before bed shortens the time to fall asleep and reduces next-day fatigue in people who sleep poorly or short. The proposed route is widening of skin blood vessels and a faster fall in core body temperature, plus action at the hypothalamic clock. Evidence comes from several small crossover trials using polysomnography (overnight instrumented sleep recording) and validated questionnaires. All were small and were run and funded by the amino acid manufacturer Ajinomoto, which has a direct commercial interest in the result.

Magnitude: Direction is consistent — shorter polysomnographic sleep-onset latency, faster entry to slow-wave sleep, and lower fatigue and sleepiness ratings at 3 g taken about one hour before bed; the published trials report within-trial significance and give no pooled effect size or absolute minutes gained. See Bannai & Kawai, 2012 and Bannai et al., 2012.

Medium 🟩 🟩

Physical Function and Muscle Strength in Older Adults

Sixteen weeks of glycine combined with N-acetylcysteine in adults aged 61–80 improved gait speed, grip strength and six-minute walk distance, alongside corrected red-cell glutathione and lower oxidative-stress markers. The proposed route is restored mitochondrial fuel oxidation. The basis is one placebo-controlled randomised trial of 24 older adults plus smaller open-label work from the same Baylor College of Medicine group, which holds patent interests in the combination. Because both amino acids were given together, glycine’s separate contribution is not isolated.

Magnitude: Direction is consistent for the combination at 1.33 mmol per kilogram per day of glycine with 0.81 mmol per kilogram per day of N-acetylcysteine over 16 weeks in adults over 60, with significant gains in gait speed, grip strength and walk distance; the published reports give no effect-size figure for these endpoints. See Kumar et al., 2023 and Kumar et al., 2021.

Lower Blood Pressure and Oxidative Stress in Metabolic Syndrome

In adults with metabolic syndrome (a cluster of raised blood pressure, raised blood sugar, central fat and abnormal blood lipids), 15 g of glycine daily for three months lowered a fat-oxidation damage marker and reduced systolic blood pressure. The proposed mechanism is restored glutathione-linked antioxidant capacity and reduced compensatory antioxidant-enzyme activity. Evidence rests on a single placebo-controlled trial of 60 volunteers; the blood-pressure effect reached significance in men only, and no cardiovascular events were measured.

Magnitude: Thiobarbituric acid reactive substances (TBARS, a marker of fat oxidation damage) fell about 25% versus placebo, superoxide dismutase (an enzyme that clears the superoxide radical) activity fell about 20%, and systolic blood pressure declined significantly in male participants (p = 0.043) over three months at 15 g daily. See Díaz-Flores et al., 2013.

Low 🟩

Reduced Schizophrenia Symptom Scores as an Add-On ⚠️ Conflicted

Added to antipsychotics other than clozapine, high-dose glycine reduced symptom scores in pooled analyses, while the largest multicentre randomised trial found none. For this audience the value is indirect: it demonstrates that gram-scale glycine reaches the brain. Net reading: any effect is small and unreliable.

Magnitude: Pooled standardised mean difference (SMD, an effect size in standard-deviation units) of −1.12 for total symptoms when added to non-clozapine antipsychotics, against a null result in a 157-patient multicentre trial. See Singh & Singh, 2011 and Buchanan et al., 2007.

Lower Coronary Artery Disease Risk ⚠️ Conflicted

Higher circulating glycine tracks with less coronary artery disease across large cohorts, and one genetic analysis supported causation partly through blood pressure. A later genetic analysis and a mouse feeding study found no causal effect. Net reading: the association is robust, but that supplementation reproduces it is unestablished.

Magnitude: Top versus bottom fifth of serum glycine among 105,718 participants gave an odds ratio (OR, the relative odds of an outcome) of 0.76, 95% confidence interval (CI, the plausible range for the estimate) 0.67–0.87, for existing disease and a hazard ratio (HR, the relative rate of new events) of 0.70, CI 0.65–0.77, for new cases; genetic causal testing was null. See Wittemans et al., 2019 and Biswas et al., 2025.

Lower Type 2 Diabetes Risk ⚠️ Conflicted

Higher circulating glycine tracks with less type 2 diabetes across prospective cohorts, and no supplementation trial has tested the link. One genetic analysis gives modest causal support; a second genetic analysis finds insulin resistance lowers glycine instead. Net reading: the association is solid, the direction of cause is not.

Magnitude: Pooled relative risk 0.89, 95% confidence interval 0.81–0.96, per standard-deviation increase in circulating glycine across eight prospective cohorts of 8,000 people including 1,940 diabetes cases; genetic causal testing is split. See Guasch-Ferré et al., 2016 and Biswas et al., 2025.

Improved Metabolic and Liver Markers in Severe Obesity

Two weeks of glycine at 100 mg per kilogram in adults with severe obesity raised plasma glycine, lowered triglycerides and liver enzymes, and improved an index linked to fatty liver disease. The study was open-label, uncontrolled and small, and glutathione itself did not change.

Magnitude: Significant within-group falls in plasma triglycerides and aminotransferases (ALT and AST, liver enzymes released when liver cells are stressed) and improvement in the glutamate-serine-glycine index across 19 participants; the report gives significance levels but no effect size or comparator group. See Tan et al., 2025.

Reduced Nighttime Urination and Urgency

Glycine taken twice daily reduced the number of nighttime voids, urgency and urge incontinence in urology outpatients with overactive-bladder symptoms. The proposed route is inhibitory glycine signalling on the spinal reflex that triggers bladder emptying. Evidence is a single 20-participant sequential placebo-then-glycine study, unrandomised and unblinded.

Magnitude: Direction is consistent at 3 g twice daily for four weeks — fewer nighttime voids, less urgency, and lower total overactive-bladder and urine-storage symptom scores; the report gives significance levels only and no effect size or between-group comparison. See Sugaya et al., 2021.

Speculative 🟨

Extension of Lifespan

Miller et al., 2019 found an 8% glycine diet extended lifespan in genetically diverse mice of both sexes, and glycine lengthens roundworm life. No human data exist; the basis is animal work only.

Skin and Connective-Tissue Support

Glycine supplies roughly a third of collagen’s amino acid residues, the structural protein of skin and tendon. No controlled trial has tested isolated glycine on skin; the basis is compositional and mechanistic only.

Enhanced Exercise Recovery and Power Output

Cell and animal work suggests glycine blunts muscle protein breakdown and lactate accumulation, and Ramos-Jiménez et al., 2024 flags possible gains in peak power and recovery. No controlled human performance trial supports this.

Benefit-Modifying Factors

  • Glycine-handling gene variants: Variants in GLDC and AMT (subunits of the enzyme complex that degrades glycine) and in SHMT2 (which converts serine to glycine) alter how much a given dose raises plasma glycine and how long it stays elevated.

  • Baseline glycine and glutathione status: Benefit is concentrated in people who start low. Older adults, people with obesity, type 2 diabetes or fatty liver consistently show depressed circulating glycine, leaving more headroom than a well-nourished younger adult has.

  • Cysteine availability: Glutathione needs cysteine as well as glycine. Where dietary sulfur amino acids are low, glycine alone will not raise glutathione, which is why the aging trials paired it with N-acetylcysteine.

  • Sex: In the metabolic syndrome trial the systolic blood pressure benefit reached significance only in men. Animal work on glutathione precursors in the aging heart likewise reports sex-divergent responses, so the female signal is weaker.

  • Pre-existing health conditions: Metabolic syndrome, obesity and fatty liver are the states in which human benefit has actually been observed. In metabolically healthy adults no controlled trial has demonstrated a benefit beyond sleep.

  • Age: Every functional benefit observed to date came from adults over 60 or from people with a disease state. Younger adults at the older end of a healthy range have no direct evidence base.

  • Methionine and protein intake: Part of glycine’s animal benefit may come from diluting methionine. A very high-protein, methionine-rich intake may therefore change what a given glycine dose does.

Potential Risks & Side Effects

High 🟥 🟥 🟥

Gastrointestinal Intolerance at Multi-Gram Doses

Nausea, soft stools, bloating and vomiting are the dose-limiting complaints. They appear once daily intake passes roughly 15–30 g and become common at 0.8 g per kilogram. The mechanism is osmotic load plus unabsorbed amino acid reaching the colon. Evidence comes from repeated schizophrenia trials dosing 30–60 g daily and from the systematic review of human glycine administration, which lists digestive complaints as the most frequent adverse event. Effects reverse on dose reduction and are uncommon at the 3–5 g used for sleep.

Magnitude: Frequency rises steeply with dose — negligible at 3–5 g daily, common above roughly 30 g daily or 0.8 g per kilogram; the published trials describe these events narratively and report no incidence rate or risk ratio. See Javitt et al., 2001 and Soh et al., 2024.

Blunting of Clozapine’s Antipsychotic Effect

In people taking clozapine, adding glycine has not helped and appears to work against it. A placebo-controlled trial found no symptom gain with added glycine while the clozapine-only arm improved markedly, and pooled analysis shows symptom scores moving in the wrong direction. The likely mechanism is competition at the N-methyl-D-aspartate receptor glycine site that clozapine already engages. This applies only to people on clozapine, but the signal is consistent across independent datasets and is a clinically meaningful loss of drug effect.

Magnitude: Positive symptoms fell 35% in the clozapine-plus-placebo arm and not at all with added glycine at 30 g daily; the pooled standardised mean difference was +0.56 in the direction of worsening for glycine added to clozapine. See Potkin et al., 1999 and Singh & Singh, 2011.

Medium 🟥 🟥

No risk reaches Medium: the remaining human safety signals rest on uncontrolled case series and single-arm open-label studies rather than on a controlled trial or consistent observational cohort data.

Low 🟥

Dilutional Hyponatraemia from Absorbed Glycine Irrigation Fluid

Glycine solution absorbed during transurethral prostate surgery causes hyponatraemia (low blood sodium), low blood pressure, nausea and transient visual disturbance. The route is surgical absorption into the circulation or surrounding tissue, not oral, but this remains the best-documented human glycine toxicity. Case-series evidence only.

Magnitude: Across 20 procedures in which 676–3,600 mL of glycine irrigant was absorbed by the extravascular route, low blood pressure occurred in 14, reduced urine output in 11, nausea in 10 and visual disturbance in 2, with hyponatraemia one third of the intravascular equivalent. See Hahn, 1993.

Rise in Circulating Homocysteine and One-Carbon Intermediates

Two weeks of glycine at 100 mg per kilogram raised plasma homocysteine, serine, cysteine and folate in adults with severe obesity. Elevated homocysteine is itself a cardiovascular risk marker. The finding comes from one small uncontrolled study and has not been replicated.

Magnitude: Significant within-group increases in plasma homocysteine and related one-carbon metabolites across 19 participants over two weeks; the report gives no absolute or percentage change and no comparator group. See Tan et al., 2025.

Speculative 🟨

Increased Oxalate Production and Stone Risk

Glycine converts to glyoxylate and partly onward to oxalate, so large loads could raise urinary oxalate and calcium-oxalate stone risk. No human supplementation study has measured this; the basis is pathway reasoning only.

Fuelling One-Carbon Metabolism in Existing Tumours

Tajan et al., 2021 showed that restricting dietary serine and glycine slows tumour growth in mice, implying added glycine might supply proliferating cells. No human data test this; the basis is animal and cell work.

Cytotoxicity at Very High Doses

Ramos-Jiménez et al., 2024 cautions that intakes above roughly 500 mg per kilogram may be cytotoxic and contribute to glutamate toxicity. The threshold sits far above supplement practice and rests on cell and animal data.

Risk-Modifying Factors

  • Clozapine treatment: The single largest risk modifier. Anyone maintained on clozapine converts glycine from a neutral supplement into an agent that measurably reduces the drug’s antipsychotic effect.

  • Kidney function: Reduced glomerular filtration slows clearance of glycine and its metabolites and raises the oxalate burden the kidney must excrete, concentrating both the stone risk and any accumulation effect.

  • AGXT and glycine-cleavage gene variants: AGXT (the enzyme that detoxifies glyoxylate) carries loss-of-function variants that cause primary hyperoxaluria (runaway oxalate production). Biallelic GLDC or AMT defects cause glycine encephalopathy (glycine accumulating in the brain).

  • Baseline biomarker levels: High baseline homocysteine, high urinary oxalate or already-elevated liver enzymes shift the risk-benefit balance, because each is a variable that glycine has been observed to move or plausibly could move.

  • Sex: Human adverse-event reporting for glycine is too sparse to establish sex differences. Preclinical work on glutathione precursors shows sex-divergent cardiac responses, so the absence of a signal is uninformative rather than reassuring.

  • Age and liver reserve: Older adults and those with advanced liver disease clear the ammonia generated by glycine breakdown more slowly, which matters at gram-scale doses and not at dietary intakes.

  • Pre-existing conditions: Recurrent calcium-oxalate stones, decompensated cirrhosis and advanced chronic kidney disease each amplify a specific glycine risk rather than adding a general one.

Key Interactions & Contraindications

  • Clozapine: Absolute caution. Glycine at gram doses reduces clozapine’s antipsychotic effect through competition at the N-methyl-D-aspartate receptor glycine site. No dose separation mitigates this; the combination is avoided.

  • Other antipsychotics (olanzapine, risperidone, haloperidol): Caution only. Glycine does not alter serum antipsychotic levels, but symptom scores may shift, so any change is monitored on a standard rating scale rather than by dose adjustment.

  • N-methyl-D-aspartate receptor modulators (D-serine, D-cycloserine, sarcosine, memantine): Caution. These act at or near the same receptor site; combined use risks additive or offsetting glutamatergic effects with no established benefit, so monitoring replaces co-administration.

  • Sedative-hypnotics (zolpidem, eszopiclone, temazepam, diazepam): Caution. Additive sedation and next-morning grogginess are plausible from glycine’s inhibitory neurotransmission. Doses are separated by at least an hour, and the hypnotic is reduced first if grogginess appears.

  • Antihypertensives (lisinopril, ramipril, losartan, amlodipine): Monitor. Glycine lowered systolic blood pressure in metabolic syndrome, so additive hypotension is possible. Home blood-pressure checks for two weeks after starting are the practical safeguard.

  • Sedating over-the-counter antihistamines (diphenhydramine, doxylamine): Caution. Additive daytime drowsiness. Separating doses is impractical for bedtime products, so the usual step is dropping one of the two.

  • Supplements with additive effects (magnesium bisglycinate, collagen peptides, gelatin, N-acetylcysteine): Monitor. Bisglycinate salts and collagen contribute meaningful glycine to the total load, and N-acetylcysteine is the intended partner for raising glutathione rather than an unwanted interaction.

  • High-dose vitamin C: Monitor. Both vitamin C and glycine feed oxalate production, so combining gram-scale doses of each raises urinary oxalate more than either alone in anyone with a stone history.

  • Anticonvulsants (valproate, divalproex, carbamazepine): Caution. Valproate raises glycine levels by inhibiting the glycine cleavage system, so supplemental glycine adds to an already elevated pool, with sedation and confusion the signals monitored.

Populations who should avoid glycine:

  • People taking clozapine
  • Primary hyperoxaluria type 1 (biallelic AGXT variants) or recurrent calcium-oxalate stones with 24-hour urinary oxalate above 40 mg
  • Advanced chronic kidney disease, eGFR (estimated glomerular filtration rate, a measure of kidney clearance) below 30 mL/min/1.73 m²
  • Decompensated cirrhosis (advanced liver scarring with failing function), Child-Pugh Class C, or any prior episode of hepatic encephalopathy (confusion caused by liver failure)
  • Inherited glycine encephalopathy or known biallelic GLDC or AMT variants
  • Pregnancy and lactation at supplemental doses, where no safety data exist

Risk Mitigation Strategies

  • Low starting dose with slow titration: Protocols typically open at 1 g nightly and rise to 3 g over 1–2 weeks, which forestalls the nausea and loose stools that are glycine’s dose-limiting adverse effect.

  • Ceiling on chronic intake: Long-term use is generally held at or below 10 g daily. Doses of 15–60 g have only been studied for 3 months or less, and gastrointestinal intolerance climbs steeply above that ceiling.

  • Full dissolution in ample fluid: The powder is usually dispersed in at least 200 mL of water. Undissolved glycine reaching the colon is the direct cause of the osmotic diarrhoea seen at higher doses.

  • Absolute avoidance on clozapine: A medication review precedes initiation. Glycine measurably reduces clozapine’s control of positive symptoms, and no timing or dose strategy offsets that loss.

  • Baseline kidney and oxalate screen for stone formers: Where a stone history exists, eGFR and a 24-hour urinary oxalate are measured beforehand, avoiding an addition to an oxalate load the kidney is already struggling with.

  • Homocysteine recheck at 12 weeks: Homocysteine is measured at baseline and again after 3 months. Glycine has raised it in one uncontrolled study, and the recheck catches a drift a single baseline cannot.

  • Blood-pressure self-monitoring on antihypertensives: Daily home readings over the first 2 weeks catch additive hypotension before it produces dizziness or falls.

  • Separation from sedatives and driving: Dosing is confined to the hour before bed and kept away from driving, so that additive sedation with hypnotics or antihistamines does not carry into waking hours.

Therapeutic Protocol

  • Standard sleep protocol: 3 g of glycine powder dissolved in water, 30–60 minutes before bed. This is the dose used across the Ajinomoto sleep trials and the one that Examine lists as the commonest consumer use.

  • Consumer-dose variant: Commercial sleep formulas commonly supply 1–2 g rather than the 3 g used in trials. No head-to-head comparison establishes whether the lower dose retains the effect, so the trial dose remains the reference point.

  • Glutathione-restoration protocol: The Baylor College of Medicine group under Rajagopal Sekhar uses glycine at about 100 mg per kilogram daily with N-acetylcysteine at about 130 mg per kilogram, split across meals, for 12–24 weeks.

  • Metabolic protocol: 15 g daily in divided doses for 3 months, the regimen used in the metabolic syndrome trial. It sits well above the sleep dose and carries a correspondingly higher gastrointestinal burden.

  • Competing approach — food-form glycine: An alternative tradition, argued by Chris Kresser among ancestral-nutrition writers, supplies glycine as gelatin, bone broth or collagen peptides rather than isolated powder. Neither approach has been tested head to head.

  • Best time of day: Bedtime for sleep effects, because the temperature drop glycine induces is only useful in the pre-sleep window. Metabolic and glutathione protocols are split across the day, where timing appears not to matter.

  • Half-life and dosing frequency: Plasma glycine peaks near 45 minutes and clears with a half-life of about an hour, so a single bedtime dose suits sleep, while daily loads above 5 g are split two to three times.

  • Genetic considerations: Variants in GLDC and AMT (the glycine-degrading complex) prolong the plasma peak, and AGXT variants (glyoxylate detoxification) argue for a lower ceiling. No routine pharmacogenetic panel currently reports these for supplement dosing.

  • Sex-based differences: The only human dose-response signal split by sex is the metabolic syndrome blood-pressure result, significant in men and not in women at the same 15 g dose. No sex-specific dose has been established.

  • Age-related considerations: Every functional benefit trial recruited adults over 60, and those at the oldest end showed the largest glutathione deficits. Slower ammonia clearance argues for staying nearer 3–5 g than 15 g past 75.

  • Baseline biomarker levels: Low fasting plasma glycine, low red-cell glutathione or elevated oxidative-stress markers identify the responders seen in trials. Normal values predict little room for a measurable change.

  • Pre-existing conditions: Metabolic syndrome, obesity and fatty liver define the populations in which oral glycine has produced measurable metabolic change; kidney and liver impairment define where the dose ceiling drops rather than rises.

Discontinuation & Cycling

  • Intended duration: Framed as continuous rather than time-limited. The sleep effect is same-night and does not persist, and the glutathione effect requires ongoing intake, so glycine behaves as a maintenance input rather than a course of treatment.

  • Withdrawal effects: None documented. No trial has reported rebound insomnia, dependence or a discontinuation syndrome after stopping glycine at any dose, including the 60 g daily used in schizophrenia trials.

  • Regression after stopping: In the aging pilot, gains in glutathione, oxidative stress, strength and cognition declined across the 12 weeks after glycine plus N-acetylcysteine was withdrawn, indicating reversal rather than a retained effect.

  • Tapering protocol: Not required. Because there is no withdrawal syndrome and no receptor adaptation described, glycine is stopped outright; tapering is only used to identify the minimum effective dose.

  • Cycling: No evidence supports cycling for efficacy. Tolerance to glycine’s sleep effect has not been reported across trials of up to 4 months, so the usual rationale for cycling does not apply.

Sourcing and Quality

  • Form to look for: Free-base crystalline glycine powder meeting United States Pharmacopeia (USP, the body that sets purity and identity standards for medicines and supplements) monograph specifications. Capsules cost more per gram and make 3 g doses awkward.

  • Purity and contaminants: Glycine is produced by chemical synthesis, so the relevant contaminants are residual solvents, chloride salts and heavy metals rather than plant adulterants. A certificate of analysis naming the USP assay range is the practical check.

  • Third-party testing: The relevant marks are NSF International, Informed Choice and USP Verified. ConsumerLab’s own 2025 assays found the glycine capsules and powders it tested matched their label claims, so cost per gram separated the products more than quality did.

  • Reputable brands: Thorne, NOW Foods, Life Extension, BulkSupplements and Ajinomoto’s own consumer line are the products most commonly named in the review literature and by practitioners; none carries an evidence advantage over the others.

  • Food-form alternatives: Gelatin and collagen peptides supply roughly 27% glycine by weight, so about 11 g of gelatin approximates a 3 g dose. Sourcing then shifts to hide origin and heavy-metal testing of the collagen.

  • Taste and formulation: Glycine is sweet and dissolves readily, which is why it appears as a flavour-masking excipient. That same property means flavoured “sleep” blends may hide a sub-gram glycine dose behind the taste.

Practical Considerations

  • Time to effect: Sleep effects appear the first night and were measured within one to three nights in trials. Metabolic and glutathione changes took 2 weeks to 6 months, with the strength and gait gains reported at 16 weeks.

  • Common pitfall — wrong dose for the goal: The 3 g sleep dose, the 100 mg per kilogram glutathione dose (7 g at 70 kg) and the 15 g metabolic dose are not interchangeable. Expecting glutathione restoration from the sleep dose is the commonest mismatch.

  • Common pitfall — glycine without cysteine: Raising glutathione needs both precursors. Glycine alone did not change glutathione in the obesity study, whereas the paired protocols did.

  • Common pitfall — ignoring hidden sources: Magnesium bisglycinate, collagen peptides and pre-workout blends all add glycine, so the effective dose is often higher than the label of any single product suggests.

  • Regulatory status: The FDA withdrew glycine’s Generally Recognized as Safe (GRAS) standing for human food and permits it only as a food additive. It is sold as a dietary supplement, not a licensed medicine, with no approved health claim and no pre-market quality check.

  • Cost and accessibility: Glycine is among the cheapest supplements available, at roughly 3–10 US cents per 3 g dose in bulk powder, and needs no prescription. Neither cost nor access is a meaningful constraint.

Interaction with Foundational Habits

  • Sleep: Direct and potentiating. Glycine’s inhibitory neurotransmission and skin vasodilation lower core temperature, the same physiological step a cool bedroom or a warm pre-bed bath produces. Combining it with those habits is redundant rather than additive, and it will not compensate for late light exposure or irregular timing.

  • Nutrition: Direct. Glycine is depleted by diets built on muscle meat and eggs, which are methionine-rich and glycine-poor. Including skin, gelatinous cuts, bone broth and collagen narrows the gap; conversely, a very high-protein intake raises the methionine load that glycine may be offsetting.

  • Exercise: Indirect and potentiating in principle. Animal and cell work suggests glycine limits muscle protein breakdown and lactate accumulation, and the paired glycine-and-cysteine trial improved strength and walk distance in older adults. No blunting of training adaptation has been reported, and no timing advantage around workouts is established.

  • Stress management: Indirect. Glycine calms spinal and brainstem signalling and can ease sleep onset in people whose sleep is disrupted by arousal, but no trial has measured cortisol or a validated stress scale after glycine. It is a downstream aid to sleep quality rather than a demonstrated stress-response modifier.

Monitoring Protocol & Defining Success

Before starting, a baseline set anchors any later change: fasting plasma glycine and homocysteine, red-cell or whole-blood glutathione where available, a metabolic panel covering fasting glucose, insulin and triglycerides, liver enzymes, serum creatinine with estimated kidney clearance, and two weeks of home blood-pressure readings. Anyone with a kidney-stone history adds a 24-hour urinary oxalate collection. Sleep is baselined for one to two weeks with a wearable or a diary, because the effect tested is a change in the individual’s own sleep-onset time rather than against a population norm.

Ongoing testing follows the protocol’s timescale. Tolerance and blood pressure are reviewed at 2 weeks, homocysteine and liver enzymes at 12 weeks, and the full panel including kidney function and oxalate at 6 months, then every 6–12 months on continued use.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Fasting plasma glycine 200–300 µmol/L Confirms the dose is reaching the bloodstream Requires a 10–12 hour fast; not offered by most routine labs, so many people track response instead
Whole-blood glutathione 1.8–2.6 mmol/L red blood cells The pathway glycine is supplemented to support Sample degrades quickly; needs a lab that stabilises it on collection. pairing with a cysteine source is required or the number will not move
Homocysteine 5–8 µmol/L Glycine has raised it in one study; a rise offsets any cardiovascular rationale Fasting; conventional labs flag only above 15 µmol/L, well above the functional target. Best paired with B12 and folate
Fasting insulin 2–5 µIU/mL Insulin resistance lowers circulating glycine and predicts who responds Fasting; conventional reference ranges extend to 25 µIU/mL, which tolerates substantial resistance
ALT and AST ALT 10–20 U/L, AST 10–25 U/L Liver enzymes fell in the obesity study and mark fatty-liver change Conventional upper limits run to 40–55 U/L, far above the functional target. Intense exercise within 48 hours of the draw invalidates the result
eGFR with serum creatinine Above 90 mL/min/1.73 m² Defines the dose ceiling and the oxalate handling capacity Normal hydration applies; creatinine rises transiently after heavy resistance training or high creatine intake
24-hour urinary oxalate Below 30 mg per 24 hours The specific risk glycine could plausibly raise through glyoxylate Only for stone formers. Collection is on a normal diet; conventional threshold for hyperoxaluria is 40–45 mg per 24 hours
Systolic blood pressure 110–120 mmHg Glycine lowered it in metabolic syndrome; additive hypotension is the concern Home readings, seated, same time daily, averaged over a week rather than a single clinic value
High-sensitivity C-reactive protein Below 1.0 mg/L Tracks the inflammation that glutathione restoration is meant to reduce Fasting preferred; a recent infection or hard training session invalidates the result, so a repeat 2 weeks later is needed
Sleep-onset latency No established target; the tracked value is the change from the individual’s own pre-glycine baseline The endpoint glycine most reliably moves Wearable estimates drift; a written sleep diary over 14 nights is more comparable than a single week of device data

Qualitative markers matter as much as the panel, because the sleep effect is subjective by nature:

  • Time to fall asleep, judged against the individual’s own two-week pre-glycine baseline
  • Next-morning grogginess or its absence, which distinguishes glycine from sedative-hypnotics
  • Daytime fatigue and mid-afternoon energy, the endpoints that moved in the sleep-restriction trial
  • Cognitive clarity and word-finding, tracked informally over months rather than days
  • Grip strength and stair-climbing ease, the practical analogues of the trial’s strength and walk-distance measures
  • Digestive comfort, which is the earliest signal that the dose has passed the tolerance threshold

Emerging Research

  • Glycine for fatty liver disease: The first dedicated trial of dietary glycine in metabolic dysfunction-associated steatotic liver disease (MASLD, fat accumulation in the liver driven by metabolic dysfunction), NCT07285135, plans 60 participants over 26 weeks with liver fat by magnetic resonance imaging as the primary endpoint.

  • Glycine and cysteine in mild cognitive impairment: NCT03493178 is an early-phase trial in 60 participants at Baylor College of Medicine with cognition as the primary outcome, testing whether the aging-hallmark findings extend to a diagnosed cognitive condition.

  • Glycine and cysteine in Alzheimer’s disease: NCT04740580 enrols 52 participants and measures cognition, brain glucose uptake and brain inflammation, the mechanistic chain that the mouse brain work proposed.

  • Evidence that could weaken the case — serine and glycine restriction in cancer: NCT07811076 tests a serine and glycine-restricted diet alongside chemoradiotherapy in 140 rectal cancer patients. A positive result would argue that surplus glycine feeds tumour metabolism.

  • Glycine in primary ciliary dyskinesia: NCT06959251 pairs glycine with magnesium and thiamine in 60 participants with primary ciliary dyskinesia (an inherited airway-clearance disorder), using respiratory exacerbation counts as the primary endpoint — a rare test of glycine against a hard clinical event.

  • The causality question: Whether circulating glycine protects the heart or merely marks metabolic health is unsettled between Wittemans et al., 2019, which found genetic support acting partly through blood pressure, and Biswas et al., 2025, which found none in humans or mice.

  • Quality of the sleep evidence: A recent mapping of glycine bioavailability and sleep outcomes, Fan et al., 2026, identifies only three supplemental glycine sleep trials and notes that the mediating role of glycine in collagen’s sleep effects has never been directly tested.

  • Lifespan replication: The mouse lifespan result of Miller et al., 2019 has not been repeated at a second dose or in a second species under the same protocol, and no human trial measures survival, so the longevity claim rests on a single animal programme.

Conclusion

Glycine is the smallest amino acid, cheap, sweet-tasting and present in every diet, with jobs spanning collagen, the body’s main internal antioxidant and a calming signal in the nervous system. The evidence divides sharply by claim. Taking a few grams before bed shortens the time to fall asleep and lowers next-day tiredness in people who sleep badly — the most repeatable finding, though the studies are small and were run by a company that sells the ingredient. Pairing glycine with a sulfur-containing partner improved walking speed, grip strength and antioxidant levels in older adults, but only in one controlled study, and the group behind it holds patents on the combination. A single trial in people with metabolic problems lowered blood pressure and oxidation markers. Longer life has been shown in mice and worms, never in people.

Against this sit real costs. Digestive upset limits the dose. Anyone taking clozapine loses part of that drug’s effect. Kidney stone risk, a rise in a heart-risk marker, and the possibility of feeding an existing tumour remain open questions rather than settled ones, because nobody has measured them properly.

The overall base is thin: many small studies, few long ones, commercial and patent interests woven through the strongest results, and a gap between what blood levels predict and what supplementation delivers.

Top - Benefits - Risks - Protocol